Please login to the form below

Not currently logged in
Email:
Password:

Veltassa

This page shows the latest Veltassa news and features for those working in and with pharma, biotech and healthcare.

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

Vifor’s Veltassa (patiromer) gained US approval in 2015 and in Europe in 2017. ... Denmark. This has given Vifor a head start overall, but Veltassa sales remain modest: it chalked up revenues of 36.8m in the first six months of 2018.

Latest news

  • Real-world data finds patients feel better on Entresto, says Novartis Real-world data finds patients feel better on Entresto, says Novartis

    Lokelma (sodium zirconium cyclosilicate or ZS-9) and Vifor Pharma’s Veltassa (patiromer) which “will be a particularly valuable addition to the clinic if efficacy can be confirmed in clinical trials”.

  • AZ gets US approval for Veltassa rival Lokelma AZ gets US approval for Veltassa rival Lokelma

    AZ gets US approval for Veltassa rival Lokelma. But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia. ... That left AZ playing catch-up in the market with Vifor’s Veltassa (patiromer), which was approved in the US

  • AZ finally gets EU nod for Veltassa rival Lokelma AZ finally gets EU nod for Veltassa rival Lokelma

    AZ finally gets EU nod for Veltassa rival Lokelma. And expects a US FDA verdict for the hyperkalaemia treatment later this year. ... challenge Vifor Pharma’s Veltassa (patiromer) which was approved in the EU last year and has been sold in the US since

  • Vifor wins European approval for Veltassa Vifor wins European approval for Veltassa

    Vifor wins European approval for Veltassa. European Commission approves the drug to treat hyperkalaemia. ... Relypsa plans to submit Veltassa applications in other markets worldwide and the product is currently under regulatory review in Switzerland and

  • FDA turns down AZ's ZS-9 once again on manufacturing issues FDA turns down AZ's ZS-9 once again on manufacturing issues

    On the plus side for AZ it seems that safety is not causing a concern for the regulator - something that resulted in rival drug Veltassa (patiromer) from Relypsa - now part of ... Veltassa was launched in early 2016 - becoming the first new drug for

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    The Vifor division, which focuses on treatments for iron deficiency, has gained a fully integrated US operation prior to the spin-out, and a complementary product in Veltassa, a potassium binder ... Veltassa was approved in late 2015 and Relypsa achieved

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics